Patient reported outcome measure applicability in clinical oncology

ABSTRACT

Patient Reported Outcomes (PROs) are a report that comes from patients on a specific subject, describing how they feel about a condition or therapy. The term includes a range of constructions and methodology and can cover concepts such as symptoms to physical assessment, well-being and social involvement. The process can be described as a measure of patient reported outcome (Patient Reported Outcome Measure - PROM). In oncology, PROMs help healthcare professionals and systems to reduce the impact of treatment on patient's quality of life. In recent years, several studies have shown improvement in the evaluated outcomes. In our country, there is still little information on this subject, especially when it comes to cancer patients. Hence, we think that it is of utmost importance to review the particularities of this tool, in order to stimulate further discussion of the subject in our country.

RESUMO

Os resultados relatados pelo paciente (RRPs) são relatórios provenientes de pacientes sobre um assunto específico, descrevendo como eles se sentem a respeito de uma condição ou terapia. O termo inclui uma gama de construções e metodologia, e pode abranger conceitos como sintomas para avaliação física, bem-estar e envolvimento social. O processo pode ser descrito como uma medida de resultado relatado pelo paciente (Patient Reported Outcome Measure - PROMs). Em oncologia, os RRPs ajudam os profissionais e sistemas de saúde a reduzir o impacto do tratamento na qualidade de vida do paciente. Nos últimos anos, diversos estudos demonstraram melhora nos resultados avaliados. Em nosso país, ainda são poucas as informações sobre o assunto, principalmente quando se trata de pacientes com câncer. Assim, pensamos ser da maior importância rever as particularidades desta ferramenta, a fim de estimular uma maior discussão sobre o assunto em nosso país.

Keywords:

Patient reported outcome measures - Medical oncology - Quality of life.

Descritores:

Medidas de resultados relatados pelo paciente - Oncologia médica - Qualidade de vida.

Publikationsverlauf

Eingereicht: 11. September 2020

Angenommen: 05. Oktober 2020

Artikel online veröffentlicht:
18. Januar 2021

• REFERENCES

• Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W.. Progress toward guidelines for the management of fatigue. Oncology 1998; Nov; 12 (11A) 369-377
• Kirkbride P, Tannock IF.. Trials in palliative treatment--have the goal posts been moved?. Lancet Oncol 2008; Feb; 9 (03) 186-187
• Diane MF, Savarese MD.. Common terminology criteria for adverse events [Internet]. Waltham. MA: UpToDate Inc; 2017. Nov cited ANO Mês dia Available from: https://www.uptodate.com/contents/common-terminology-criteriafor-adverse-events
• Wilson R.. Patient led PROMs must take centre stage in cancer research. Res Involv Engagem 2018; 4 (01) 7
• Richards MJ, Corner J, Maher J.. The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors. Br J Cancer 2011; Nov; 105 (Suppl 1): S1-S4
• Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S. et al Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; Nov/Dec; 10 (Suppl 2): S125-S37
• Williams K, Sansoni J, Morris D, Grootmaat P, Thompson C.. Patient-reported outcome measures. Literature review. Sydney: Australian Commission on Safety and Quality in Health Care;; 2016
• Maharaj AD, Samoborec S, Evans SM, Zalcberg J, Neale RE, Goldstein D. et al Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. HPB (Oxford) 2019; Feb; 22 (02) 187-203
• Alrubaiy L, Hutchings HA, Williams JG.. Assessing patient reported outcome measures: a practical guide for gastroenterologists. United European Gastroenterol J 2014; Dec; 2 (06) 463-470
• Black N.. Patient reported outcome measures could help transform healthcare. BMJ 2013; 346: f167
• Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH.. Maximising the impact of patient reported outcome assessment for patients and society. BMJ 2019; Jan; 364: k5267
• Rotenstein LS, Huckman RS, Wagle NW.. Making patients and doctors happier - the potential of patient-reported outcomes. N Engl J Med 2017; Oct; 377 (14) 1309-1312
• Kargo AS, Coulter A, Jensen PT, Steffensen KD.. Proactive use of PROMs in ovarian cancer survivors: a systematic review. J Ovarian Res 2019; 12: 63
• Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C. et al Overall survival results of a trial assessing patientreported outcomes for symptom monitoring during routine cancer treatment. JAMA 2017; Jul; 318 (02) 197-198
• Kindts I, Laenen A, Van Den Akker M, Weltens C.. PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study. Nature 2019; Nov; 27 (11) 4123-4132
• Prasad V.. Do cancer drugs improve survival or quality of life?. BMJ 2017; Oct; 359: j4528
• Kim C, Prasad V.. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 2015; Dec; 175 (12) 1992-1994
• Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A.. Availability of evidence on overall survival and quality of life benefits of cancer drugs approved by the European Medicines Agency: retrospective cohort study of drug approvals from 2009-2013. BMJ 2017; Oct; 359: j4530
• Sørensen JB, Klee M, Palshof T, Hansen HH.. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; Apr; 67 (04) 773-775
• Braga S.. Why do our patients get chemotherapy until the end of life?. Ann Oncol 2011; Nov; 22 (11) 2345-2348
• National Confidential Enquiry into Patient Outcome and Death (NCEPOD). For better, for worse?. A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy. London: NCEPOD;; 2008
• Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL.. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials 2015; Jul; 43: 1-9
• Porter ME, Larsson S, Lee TH.. Standardizing patient outcomes measurement. N Engl J Med 2016; Feb; 374 (06) 504-506
• Mastropietro AP, Oliveira EA, Santos MA, Voltarelli JC.. Functional assessment of cancer therapy bone marrow transplantation: portuguese translation and validation. Rev Saúde Pública 2007; Apr; 41 (02) 260-268
• Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA. et al Landscape of healthrelated quality of life in patients with early-stage pancreatic cancer receiving adjuvant or neoadjuvant chemotherapy a systematic literature review. Pancreas 2020; Mar; 49 (03) 393-407
• Fox RS, Moreno PI, Yanez B, Estabrook R, Thomas J, Bouchard LC. et al Integrating PROMIS® computerized adaptive tests into a web-based intervention for prostate cancer. Health Psychol 2019; May; 38 (05) 403-409
• Lane A, Metcalfe C, Young GJ, Peters Tj, Blazeby J, Avery KNL. et al Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU Int 2016; Dec; 118 (06) 869-879
• Hoque DE, Earnest A, Ruseckaite R, Lorgelly P, Sampurno F, Evans M. et al A randomised controlled trial comparing completeness of responses of three methods of collecting patient-reported outcome measures in men diagnosed with prostate cancer. Qual Life Res 2019; Mar; 28 (03) 687-694
• Cuypers M, Lamers RED, Kil PJM, Van de PollFranse LV, Vries M.. Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the Prostate Cancer Patient Centered Care trial. Support Care Cancer 2018; Nov; 26 (11) 3739-3748
• Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R. et al Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with nonsmall cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 2018; Jun; 27 (06) 1563-1570
• Lenderking WR, Lin H, Speck RM, Zhu Y, Huang H, Huang J. et al Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). Future Oncol 2019; Aug; 15 (24) 2841-2855
• Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C. et al Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapy. Clin Lung Cancer 2018; Jan; 19 (01) 74-83.e11
• Lee CK, Novello S, Rydén A, Mann H, Mok T.. Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial. J Clin Oncol 2018; Jun; 36 (18) 1853-1860
• Wu Y, Hirsh V, Sequist LV, Hu HP, Feng J, Lu S. et al Does EGFR mutation type influence patientreported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large, phase III studies comparing afatinib with chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient 2018; Feb; 11 (01) 131-141
• Sebastian M, Rydén A, Walding A, Papadimitrakopoulou V.. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2018; Aug; 122: 100-106
• Bordoni R, Ciardiello F, Von Pawel J, Cortinovis D, Karagiannis T, Ballinger M. et al Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer 2018; Sep; 19 (05) 441-449.e4
• Brown JC, Damjanov N, Courneya KS, Troxel AB, Zemel BS, Rickels MR. et al A randomized dose-response trial of aerobic exercise and healthrelated quality of life in colon cancer survivors. Psychooncology 2018; Apr; 27 (04) 1221-1228
• Price BA, Bednarski BK, You YN, Manandhar M, Dean EM, Alawadi ZM. et al Accelerated enhanced recovery after minimally invasive colorectal cancer surgery (RecoverMI trial). BMJ Open 2017; Jul; 7 (07) e015960
• Blaby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD.. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 2014; Dec; 66 (06) 1148-1156
• Staehler M, Motzer RJ, George DJ, Pandha HS, Donsokv F, Escudier B. et al Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 2018; Oct; 29 (10) 2098-2104
• Abernethy AP, Herndon IJE, Wheeler JL, Day JM, Hood L, Patwardhan M. et al Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manage 2009; Jun; 37 (06) 1027-1038
• Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ. et al Automated pain intervention for underserved minority women with breast cancer. Cancer 2015; Jun; 121 (11) 1882-1880
• Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D. et al The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat 2012; Aug; 134 (03) 1327-1335